Maternal Antibodies to Dietary Antigens and Risk for Nonaffective Psychosis in Offspring
Publication: American Journal of Psychiatry
Abstract
Objective:
The authors analyzed archival dried blood spots obtained from newborns to assess whether levels of immunoglobulin G (IgG) directed at dietary antigens were associated with a later diagnosis of a nonaffective psychotic disorder.
Method:
The study population consisted of individuals born in Sweden between 1975 and 1985 with verified register-based diagnoses of nonaffective psychoses made between 1987 and 2003 and comparison subjects matched on sex, date of birth, birth hospital, and municipality. A total of 211 case subjects and 553 comparison subjects consented to participate in the study. Data on factors associated with maternal status, pregnancy, and delivery were extracted from the Swedish Medical Birth Register. Levels of IgG directed at gliadin (a component of gluten) and casein (a milk protein) were analyzed in eluates from dried blood spots by enzyme-linked immunosorbent assay. Odds ratios were calculated for levels of IgG directed at gliadin or casein for nonaffective psychosis.
Results:
Levels of anti-gliadin IgG (but not anti-casein IgG) above the 90th percentile of levels observed among comparison subjects were associated with nonaffective psychosis (odds ratio=1.7, 95% CI=1.1–2.8). This association was not confounded by differences in maternal age, immigrant status, or mode of delivery. Similarly, gestational age at birth, ponderal index, and birth weight were not related to maternal levels of anti-gliadin IgG.
Conclusions:
High levels of anti-gliadin IgG in the maternal circulation are associated with an elevated risk for the development of a nonaffective psychosis in offspring. Research is needed to identify the mechanisms underlying this association in order to develop preventive strategies.
A number of adverse exposures in utero or in the neonatal period have been associated with the later development of schizophrenia and other nonaffective psychoses. These include exposures to maternal malnutrition or infections and complications of pregnancy and birth (1). The mechanisms underlying these associations are unknown, and a variety of hypotheses have been tested experimentally. For example, animal studies suggest that activation of maternal immune responses during fetal development can cause behavioral deficits involving both cognitive and emotional domains in adult offspring (2). Indeed, reports of an elevated risk for schizophrenia among offspring of women with high blood levels of interleukin-8 (3) or tumor necrosis factor-α (4) during pregnancy support this notion. A register-based study by Eaton et al. (5) indicated that chronic inflammatory or autoimmune conditions, such as celiac disease, are more common among parents of patients with schizophrenia than among comparison parents.
A number of studies have also indicated immune activation or dysregulation in patients at the time of the first manifestations of schizophrenia and other nonaffective psychoses. Such studies include reports of altered levels of chemokines and cytokines (6, 7) and of antibodies directed at immune targets derived from infectious agents (8, 9), dietary proteins (10, 11), and self-antigens (12).
Recent studies have illustrated the usefulness of archival dried blood samples collected prospectively during neonatal screening for metabolic disorders (e.g., phenylketonuria) as a source of information on early life exposures that may be associated with diseases that have an adult onset. Such studies have reported an association between high levels of immunoglobulin G (IgG) directed at the protozoan Toxoplasma gondii (13) and at herpes simplex virus type 2 (14) and the future development of schizophrenia. IgG is actively transported across the placenta during the later stages of pregnancy to provide passive immunization of the fetus (15), and hence such antibodies reflect maternal exposures and immune responses to specific antigens. Using dried blood spots obtained from newborns, we investigated whether levels of IgG directed at food-derived antigens, namely, gliadin (a component of wheat gluten) and casein (a bovine milk protein), were associated with a later diagnosis of a nonaffective psychosis.
Method
The study population consisted of individuals born in Sweden between 1975 and 1985. Case subjects were diagnosed with nonaffective psychoses (see diagnoses below) as inpatients between 1987 and 2003 or as outpatients between 1997 and 2003, in Stockholm County Council. Inpatient data were extracted from the National Patient Register, and outpatient data from a local psychiatric health care registration system (the Psychiatric Care System) used in Stockholm County Council. To be included in the study, case subjects had to be alive (20 were deceased), be residents of Sweden (two had emigrated), and have a registered address (24 did not). By these criteria, 739 eligible case subjects were identified after verification of diagnoses in medical records at the different psychiatric clinics by two trained psychiatric nurses, and all were contacted. Of these, 337 (45.6%) did not respond to contact and 139 (18.8%) declined to participate, leaving a final sample of 263 case subjects (participation rate, 35.6%).
The comparison subjects were selected from a population-based register at the National Board of Health and Welfare and matched for sex, date of birth, birth hospital, and municipality. Letters were sent to potential participants with the aim of recruiting four matched comparison subjects per case subject. To be included in the study, comparison subjects could not have a history of inpatient psychiatric admission (according to the National Patient Register), had to be alive (two of those initially selected were deceased), had to be residents of Sweden (16 of those initially selected had emigrated), and had to have a registered address (38 of those initially selected did not). A total of 1,553 eligible subjects were identified. Of these, 660 (42.5%) did not respond to contact and 244 (15.7%) declined to participate, leaving 649 comparison subjects (participation rate, 41.8%). Thus, significantly more comparison subjects than case subjects consented to participate (χ2=8.0, df=1, p=0.005). Given the number of potential comparison subjects who declined to participate, the majority of case subjects (79.2%) had fewer than four matched comparison subjects.
Diagnoses
Nonaffective psychoses were defined according to DSM-IV, ICD-9, or ICD-10 codes. For schizophrenia, we used DSM-IV codes 295.x, excluding 295.7; ICD-9 codes 295.x, excluding F and H; and ICD-10 code F20. For other nonaffective psychoses, we used DSM-IV code 295.7 for schizoaffective disorders, code 297.1 for persistent delusional disorders, code 297.3 for induced delusional disorder, code 298.8 for acute and transient psychotic disorders, code 298.9 for unspecified nonorganic psychosis, and code 301.22 for schizotypal disorder; we used ICD-9 code 295F for schizotypal disorder, code 295H for schizoaffective disorders, code 297 for delusional disorders, and code 298 excluding A and B for reactive psychoses (excluding depressive and manic psychoses); we used ICD-10 code F21 for schizotypal disorder, code F22 for persistent delusional disorders, code F23 for acute and transient psychotic disorders, code F24 for induced delusional disorder, code F25 for schizoaffective disorders, code F28 for other nonorganic psychotic disorders, and code F29 for unspecified nonorganic psychosis.
Data From the Swedish Medical Birth Register
The Swedish Medical Birth Register, which was initiated in 1973, includes information for all deliveries in Sweden as well as data from the prenatal and neonatal periods. From the Register, we collected information on gestational age, weight, and length at birth for offspring, as well as data on maternal immigration and maternal age at delivery.
Blood Spots
In Sweden, blood is collected on a filter from all newborns in a screening program for early detection of metabolic diseases (e.g., phenylketonuria). Since 1975, these dried blood filters have been stored at Karolinska University Hospital, Huddinge. For this study, one blood spot from each consenting participant was excised from the filter and transferred to an individual resealable plastic bag. Filters were retrieved for 874 (252 case subjects and 622 comparison subjects) of the 912 (95.8%) individuals who consented to the study, with no significant difference between the two groups. Of these, 211 case subjects and 553 comparison subjects were matched sets.
Processing and Analyses
A disk 3.2 mm in diameter was punched from each blood spot and distributed into deep 96-well plates sealed with AxyMats (Axygen, Union City, Calif.). Proteins were eluted from the filter paper by incubation in 100 μL of phosphate-buffered saline for 1 hour at 37°C. Levels of IgG antibodies directed at whole casein or gliadin in the eluates were measured by solid-phase enzyme-linked immunosorbent assay, as previously described (10, 16). The levels of antibodies were analyzed as the 75th, 90th, and 95th percentiles of reactivity, as previously described (10); the cutoff points were based on the distribution among comparison subjects. During processing, all personnel were blind to case-control status of the filters.
Statistical Analysis
Conditional logistic regression for matched data were used in this case-control study. Potential confounding by maternal age, immigration status, or other factors related to pregnancy or birth, not matched for, was considered in these analyses. Logistic regression was used to analyze the association between potential confounders and high levels of gliadin and casein. SAS, version 9.1 (SAS Institute, Cary, N.C.), was used in all statistical analyses.
Approval
The study was approved by the regional research ethics committee at Karolinska Institute, Stockholm. After receiving a complete description of the study, participants provided written informed consent.
Results
The characteristics of the sample are presented in Table 1. These data include the proportions of patients in different diagnostic groups as well as birth years and sex distributions (matching criteria). The table also includes data on covariates of interest: maternal immigration, maternal age, delivery by cesarean section, parity, and social and pregnancy factors (not matched for).
| Characteristic | Case Subjects (N=211) | Comparison Subjects (N=553) | ||
|---|---|---|---|---|
| N | % | N | % | |
| Schizophrenia | 51 | 24.2 | ||
| Other nonaffective psychoses | 160 | 75.8 | ||
| Sex | ||||
| Men | 116 | 55.0 | 270 | 48.8 |
| Women | 95 | 45.0 | 283 | 51.2 |
| Birth year | ||||
| 1975–1977 | 85 | 40.3 | 224 | 40.5 |
| 1978–1980 | 65 | 30.8 | 175 | 31.6 |
| 1981–1985 | 61 | 28.9 | 154 | 27.9 |
| Maternal age ≥35 years | 28 | 13.3 | 47 | 8.5 |
| Maternal immigration | 47 | 22.3 | 73 | 13.2 |
| Parity | ||||
| 1 | 98 | 46.5 | 256 | 46.3 |
| 2 | 78 | 37.0 | 208 | 37.6 |
| ≥3 | 35 | 16.6 | 89 | 16.1 |
| Cesarean section | 18 | 8.5 | 67 | 12.1 |
| Maternal marital status at first antenatal visit (1975–1981)a | ||||
| Married | 99 | 61.1 | 257 | 61.5 |
| Never married | 58 | 35.8 | 149 | 35.6 |
| Other | 5 | 3.1 | 12 | 2.9 |
| Parents cohabiting at first antenatal visit (1982–1985)b | 21 | 87.5 | 57 | 91.9 |
| Mean | SD | Mean | SD | |
| Birth weight (grams)c | 3,430.6 | 570.0 | 3,487.7 | 558.3 |
| Gestational age at birth (weeks)d | 39.5 | 1.9 | 39.7 | 1.7 |
| Ponderal indexe | 27.0 | 2.7 | 27.3 | 2.7 |
a
Missing data for nine case subjects and 34 comparison subjects born 1975–1981.
b
Missing data for 16 case subjects and 39 comparison subjects born 1982–1983.
c
Missing data for one case subject and two comparison subjects.
d
Missing data for one case subject and 10 comparison subjects.
e
Missing data for one case subject and three comparison subjects.
IgG Levels and Nonaffective Psychosis
A significantly elevated risk for nonaffective psychoses was associated with high levels (90th percentile) of IgG anti-gliadin antibodies (odds ratio=1.7, 95% confidence interval [CI]=1.1–2.8) but not anti-casein antibodies (odds ratio=0.8, 95% CI=0.4–1.5) (Table 2, Figure 1). The risk for future nonaffective psychosis increased further with levels of anti-gliadin antibodies at the 95th percentile (odds ratio=2.5, 95% CI=1.4–4.5).
| Exposed Subjects (N) | Model 1b | Model 2c | Model 3d | Model 4e | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Antigen and Antibody Level Percentilea | Case Subjects (N=211) | Comparison Subjects (N=553) | Odds Ratio | 95% CI | Odds Ratio | 95% CI | Odds Ratio | 95% CI | Odds Ratio | 95% CI |
| Gliadin | ||||||||||
| 75th | 55 | 136 | 1.0 | 0.7–1.5 | 1.0 | 0.7–1.5 | 1.1 | 0.7–1.6 | 1.1 | 0.7–1.6 |
| 90th | 34 | 54 | 1.7 | 1.1–2.8 | 1.7 | 1.1–2.8 | 1.8 | 1.1–2.9 | 1.8 | 1.1–2.9 |
| 95th | 23 | 27 | 2.5 | 1.4–4.5 | 2.5 | 1.4–4.4 | 2.6 | 1.4–4.7 | 2.6 | 1.4–4.8 |
| Casein | ||||||||||
| 75th | 45 | 133 | 0.9 | 0.6–1.4 | 0.9 | 0.6–1.4 | 0.9 | 0.6–1.3 | 0.9 | 0.6–1.4 |
| 90th | 16 | 50 | 0.8 | 0.4–1.5 | 0.8 | 0.4–1.6 | 0.8 | 0.4–1.5 | 0.8 | 0.4–1.5 |
| 95th | 10 | 27 | 0.9 | 0.4–2.0 | 0.9 | 0.4–2.1 | 0.9 | 0.4–2.0 | 0.9 | 0.4–1.9 |
a
Percentiles are based on levels observed among comparison subjects.
b
Matched for sex, date of birth, birth hospital, and municipality.
c
Model 1 with the addition of maternal age.
d
Model 1 with the addition of maternal age and maternal immigration.
e
Model 1 with the addition of maternal age, immigration, and cesarean section.
Potential Confounding by Maternal Age, Immigration, or Mode of Delivery
Among the individuals included in the study, the mothers of case subjects were slightly older on average at the time of delivery than the mothers of comparison subjects. Hence, maternal age ≥35 years was associated with a higher risk of developing nonaffective psychosis (odds ratio=1.8, 95% CI=1.1–3.2). Maternal immigration to Sweden was also associated with an elevated risk for nonaffective psychosis in offspring (odds ratio=2.0, 95% CI=1.3–3.1) (Table 3). While age, dietary habits, and mode of delivery can potentially influence levels of IgG directed at dietary antigens, no significant association between maternal age, immigrant status, or cesarean section and levels of IgG directed at gliadin or casein was observed in this sample (see Table 3). These three variables were nevertheless included in the model (see models 2–4) but did not affect the risk estimates for nonaffective psychoses associated with levels of IgG toward dietary antigens (see Table 2). Hence, the risk associated with high levels of IgG anti-gliadin antibodies appears to act independently of maternal age, immigration, and mode of delivery.
| High Anti-Casein Antibody Level | High Anti-Gliadin Antibody Level | Nonaffective Psychosis | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Nb | Odds Ratio | 95% CI | Nb | Odds Ratio | 95% CI | Nb | Odds Ratio | 95% CI |
| Maternal age ≥35 years | 7/68 | 1.1 | 0.5–2.5 | 6/69 | 0.6 | 0.3–1.5 | 28/47 | 1.8 | 1.1–3.2 |
| Maternal immigration | 14/106 | 1.5 | 0.8–2.8 | 10/110 | 0.7 | 0.3–1.3 | 47/73 | 2.0 | 1.3–3.1 |
| Cesarean section | 5/80 | 0.6 | 0.2–1.6 | 10/75 | 1.0 | 0.5–2.1 | 18/67 | 0.6 | 0.3–1.1 |
a
High levels of antibodies are defined as being in the 90th percentile of levels observed among comparison subjects.
b
Numbers of case and comparison subjects.
Gliadin Antibodies and Complications During Pregnancy and Delivery
High levels of IgG anti-gliadin antibodies are often observed in patients with untreated celiac disease (17), and it has been reported that untreated celiac disease in pregnant women is a risk factor for adverse pregnancy outcomes, such as low birth weight and babies who are small for gestational age (18–20). Moreover, the bulk of fetal IgG is transferred from the mother during the last 4 weeks of the pregnancy (15). We therefore used data from the Swedish Medical Birth Register to test whether birth weight, length, and gestational age at birth were associated with levels of IgG anti-gliadin antibodies. Mean birth weight, ponderal index (weight/length [3]), and gestational age across exposures (above and below the 90th percentile of antibodies to casein or gliadin) and outcomes (case and comparison subjects) are presented in Table 4. None of these measures differed significantly across exposures or outcomes. Thus, fetal growth or gestational age at birth did not appear to modify the association between elevated IgG levels and nonaffective psychoses observed in this sample.
| Case Subjects | Comparison Subjects | |||||
|---|---|---|---|---|---|---|
| Variable and Exposurea | N | Mean | SD | N | Mean | SD |
| Birth weight (grams) | ||||||
| Gliadin-IgG < 90th percentile | 176 | 3,404.2 | 571.4 | 497 | 3,489.8 | 566.4 |
| Gliadin-IgG ≥ 90th percentile | 34 | 3,567.1 | 551.1 | 54 | 3,468.2 | 481.2 |
| Ponderal index (kg/m3) | ||||||
| Gliadin-IgG < 90th percentile | 176 | 27.0 | 2.7 | 496 | 27.3 | 2.7 |
| Gliadin-IgG ≥ 90th percentile | 34 | 27.2 | 2.6 | 54 | 26.7 | 2.6 |
| Gestational age (weeks) | ||||||
| Gliadin-IgG < 90th percentile | 176 | 39.4 | 2.0 | 489 | 39.8 | 1.8 |
| Gliadin-IgG ≥ 90th percentile | 34 | 39.7 | 1.5 | 54 | 39.6 | 1.6 |
a
Percentiles of antibody levels are based on levels observed among comparison subjects.
Nonparticipation and Loss to Follow-Up
As noted earlier, significantly more case subjects (64%) than comparison subjects (58%) contacted did not consent to participate. Case subjects who did not provide consent did not differ significantly in distribution of birth year, sex, and diagnosis from those who did (Table 5).
| Consented (N=263) | Did Not Consent (N=476) | |||
|---|---|---|---|---|
| Variable | N | % | N | % |
| Birth year | ||||
| 1975–1977 | 111 | 42.2 | 211 | 44.3 |
| 1978–1980 | 82 | 31.2 | 145 | 30.5 |
| 1981–1985 | 70 | 26.6 | 120 | 25.2 |
| Sex | ||||
| Female | 116 | 44.1 | 201 | 42.2 |
| Male | 147 | 55.9 | 275 | 57.8 |
| Diagnosis (ICD-10 codes) | ||||
| Schizophrenia (F20) | 63 | 24.0 | 104 | 21.8 |
| Other disorders (F21–F29) | 200 | 76.0 | 372 | 78.2 |
a
No significant differences between groups.
Discussion
We report on an elevated risk for developing nonaffective psychoses associated with high levels of antibodies directed at gliadin, a component of wheat, in dried blood spots obtained during the neonatal period. No such risk was associated with high levels of antibodies directed at casein, a dietary antigen abundant in cow's milk. The association between these antibodies in perinatal blood samples and the subsequent development of psychosis has not been previously investigated.
Antibodies of the IgG class detected in the neonatal blood samples are predominantly derived from the maternal circulation and transferred across the placenta during pregnancy (15). These antibodies are therefore likely to represent maternal reactivity to gliadin and thus suggest that mothers who produce high levels of these antibodies during pregnancy give birth to children who have an elevated risk of developing a nonaffective psychosis later in life. We did not find an association with antibodies to casein, suggesting that the risk is not associated with an overall increase in antibodies to food antigens. While maternal age and immigration were associated with an elevated risk for nonaffective psychosis in the offspring, neither these factors nor mode of delivery contributed to the association between high IgG levels and risk of psychosis in the offspring.
IgG anti-gliadin antibodies are often, but not exclusively (see below), observed in individuals with celiac disease. Celiac disease is a rare condition affecting approximately 1% of the population. It is characterized by an autoimmune enteropathy triggered by ingestion of gluten (21). Several studies have reported that untreated maternal celiac disease (but not treated disease) increases the risk for adverse pregnancy outcomes, such as low birth weight, intrauterine growth restriction, and prematurity (18–20). The mechanisms underlying these associations are not known with certainty but are believed to involve both autoantibodies affecting placental function (22, 23) and maternal malnutrition due to intestinal malabsorption (19). While the adverse birth outcomes associated with untreated maternal celiac disease are also risk factors for a later diagnosis of psychosis (24, 25), we found no evidence for restricted fetal growth (as measured by birth weight and ponderal index) being involved in the association between high levels of IgG anti-gliadin antibodies and risk for nonaffective psychosis in the offspring.
Since the bulk of the IgG present in the neonate at birth is transferred across the placenta during the last month of pregnancy, difference in gestational length is another factor that can lead to differences in levels of maternal IgG detected in the neonatal circulation. Gestational age did not, however, differ significantly across levels of gliadin antibodies among case or comparison subjects in our sample. Taken together, these observations suggest that fetal malnutrition due to subclinical maternal celiac disease or other causes is unlikely to explain the association between maternal levels of anti-gliadin IgG and the development of psychosis in offspring.
Other mechanisms explaining the association between maternal antibodies to gliadin and the subsequent development of psychiatric disorders in offspring need to be considered. Tentatively, our findings may represent common genetic factors for increased gluten sensitivity and celiac disease and psychotic disorders. Along these lines, Eaton et al. (5), using Danish population registers, reported an overrepresentation of celiac disease among patients with schizophrenia as well as among their parents. Elevated levels of markers of celiac disease have also been observed in patients with psychiatric disorders (26–29). It should be noted, though, that while levels of IgG directed at gliadin are higher in these patients than in comparison subjects, their immune response to gliadin often appears to differ from that observed in patients with celiac disease, and they do not appear to generate antibodies against autoantigens commonly observed in patients with celiac disease (10, 29, 30). Moreover, genome-wide association studies of schizophrenia indicate that the HLA-DQA*0501 and DQB*0201 alleles, present in almost 90% of patients with celiac disease (31), are not overrepresented among schizophrenia patients (10) and even appear to be associated with a lower risk for schizophrenia (32). Studies of non-HLA genes have so far failed to identify common genetic risk factors for celiac disease and schizophrenia (33). The existence of genetic factors common to elevated levels of IgG anti-gliadin antibodies and nonaffective psychoses, other than schizophrenia, remains to be determined.
Elevated levels of IgG anti-gliadin antibodies are also observed in individuals who do not meet the criteria for celiac disease. Gluten sensitivity is a clinical entity used to describe individuals who do not exhibit the autoimmune component of celiac disease but who experience distress following gluten ingestion and who have heightened levels of IgG (and IgA) anti-gliadin antibodies (34). Moreover, studies from the United Kingdom (35) and Sweden (36) report that 10%–20% of the general population have IgG antibodies to gliadin in the absence of other markers of celiac disease, which agrees well with our findings of a risk confined to the highest decile. Therefore, to effectively confirm or rule out celiac disease in the mothers, serological tests more specific for celiac disease, such as measurements of maternal IgA antibodies to gliadin and antibodies directed at tissue transglutaminase, should be performed in future studies when maternal plasma is available (17). Insufficient material and the fact that maternal IgA antibodies (the measurement of which is required for the full assessment of celiac disease) do not readily cross the placenta prevented us from further characterizing the maternal response to gliadin in the present study.
Another mechanism potentially linking maternal anti-gliadin reactivity with the later development of psychosis in offspring involves maternal inflammation. Celiac disease is associated with chronic inflammation of the small intestine (37). Heightened sensitivity to gluten can also be observed in patients with functional gastrointestinal disorders caused by infections or other causes (38). Moreover, patients with gluten sensitivity appear to exhibit a strong activation of the innate immune response (34). Therefore, it is possible that mothers with high levels of anti-gliadin antibodies suffer from some degree of inflammation (39), which can affect the developing fetus. As mentioned earlier, several experimental reports support this notion (2). Direct evidence for an association between elevated maternal levels of inflammatory mediators and the development of psychosis in offspring has also been reported (3, 4).
Finally, the association between maternal gliadin antibodies and the development of psychosis in offspring can potentially be explained by maternal diet. Indeed, ingested gluten has been proposed to have direct effects on neuronal function, a thesis supported by both clinical (40, 41) and experimental studies (42). However, the potential effects of exposure to dietary gluten during early life have not been investigated.
Strengths and Limitations
This study was based on archived samples from the neonatal period. These samples provide an invaluable source of information on early life exposures associated with illnesses later in life. Some limitations should be noted, however. The numbers of case and comparison subjects were limited because of fairly high losses to follow-up, which were somewhat higher among case subjects than among comparison subjects. This is not unexpected given that the case subjects suffer from a serious psychiatric condition. Consequently, there may be a selection bias in this study, which should be kept in mind when considering the generalizability of the results. Insofar as we can assess this bias, it should be noted that case subjects who consented to the study did not differ significantly in age, sex, or diagnosis from those who did not.
Another limitation is that the diagnoses in the study are register-based. Diagnoses from the National Patient Register (43, 44) as well as the Psychiatric Care System (43, 44) have, however, been validated and have proven to be of excellent quality. Moreover, in our consent procedure, a verification of registered diagnoses was required before contact with case subjects, allowing us to exclude individuals with erroneous register-based diagnoses. While case and comparison subjects were carefully matched on a number of demographic parameters, maternal factors that were not available to us in this study (e.g., medical diagnoses and dietary habits) could potentially modify or confound the associations observed.
Conclusions
To our knowledge, this is the first study to show an association between high levels of maternal antibodies directed at gliadin and the later development of nonaffective psychoses in offspring. Future studies should focus on identifying the underlying mechanisms of this association in order to develop preventive strategies. It is notable that antibodies to gliadin can be safely reduced in pregnant women by the limitation of gluten-containing foods from the diet (45), and additional therapies are under development (46). It is also promising that the risk of adverse birth outcomes among women with undiagnosed celiac disease more or less disappears after diagnosis and treatment (19). The further delineation of the mechanisms that link gluten sensitivity with risk of psychiatric disorders may thus lead to new methods for the prevention and treatment of these disorders.
Footnote
Received Aug. 8, 2011; revision received Dec. 16, 2011; accepted Jan. 17, 2012
References
1.
Brown AS: The environment and susceptibility to schizophrenia. Prog Neurobiol 2011; 93:23–58
2.
Meyer U, Feldon J: Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behav Brain Res 2009; 204:322–334
3.
Brown AS, Hooton J, Schaefer CA, Zhang H, Petkova E, Babulas V, Perrin M, Gorman JM, Susser ES: Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring. Am J Psychiatry 2004; 161:889–895
4.
Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Wagner RL, Yolken RH: Maternal cytokine levels during pregnancy and adult psychosis. Brain Behav Immun 2001; 15:411–420
5.
Eaton WW, Byrne M, Ewald H, Mors O, Chen CY, Agerbo E, Mortensen PB: Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 2006; 163:521–528
6.
Soderlund J, Schroder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H, Erhardt S, Engberg G: Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry 2009; 14:1069–1071
7.
Reale M, Patruno A, De Lutiis MA, Pesce M, Felaco M, Di Giannantonio M, Di Nicola M, Grilli A: Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 2011; 12:13
8.
Niebuhr DW, Millikan AM, Cowan DN, Yolken R, Li Y, Weber NS: Selected infectious agents and risk of schizophrenia among US military personnel. Am J Psychiatry 2008; 165:99–106
9.
Pedersen MG, Stevens H, Pedersen CB, Nørgaard-Pedersen B, Mortensen PB: Toxoplasma infection and later development of schizophrenia in mothers. Am J Psychiatry 2011; 168:814–821
10.
Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Leister F, Yang S, Krivogorsky B, Alaedini A, Yolken R: Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia. Biol Psychiatry 2010; 68:100–104
11.
Niebuhr DW, Li Y, Cowan DN, Weber NS, Fisher JA, Ford GM, Yolken R: Association between bovine casein antibody and new onset schizophrenia among US military personnel. Schizophr Res 2011; 128:51–55
12.
Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, Coles AJ, Vincent A, Lennox BR: Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011; 258:686–688
13.
Mortensen PB, Norgaard-Pedersen B, Waltoft BL, Sorensen TL, Hougaard D, Torrey EF, Yolken RH: Toxoplasma gondii as a risk factor for early-onset schizophrenia: analysis of filter paper blood samples obtained at birth. Biol Psychiatry 2007; 61:688–693
14.
Mortensen PB, Pedersen CB, Hougaard DM, Norgaard-Petersen B, Mors O, Borglum AD, Yolken RH: A Danish national birth cohort study of maternal HSV-2 antibodies as a risk factor for schizophrenia in their offspring. Schizophr Res 2010; 122:257–263
15.
Saji F, Samejima Y, Kamiura S, Koyama M: Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod 1999; 4:81–89
16.
Severance EG, Dickerson FB, Halling M, Krivogorsky B, Haile L, Yang S, Stallings CR, Origoni AE, Bossis I, Xiao J, Dupont D, Haasnoot W, Yolken RH: Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr Res 2010; 118:240–247
17.
van der Windt DA, Jellema P, Mulder CJ, Kneepkens CM, van der Horst HE: Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. JAMA 2010; 303:1738–1746
18.
Khashan AS, Henriksen TB, Mortensen PB, McNamee R, McCarthy FP, Pedersen MG, Kenny LC: The impact of maternal celiac disease on birthweight and preterm birth: a Danish population-based cohort study. Hum Reprod 2010; 25:528–534
19.
Ludvigsson JF, Montgomery SM, Ekbom A: Celiac disease and risk of adverse fetal outcome: a population-based cohort study. Gastroenterology 2005; 129:454–463
20.
Norgard B, Fonager K, Sorensen HT, Olsen J: Birth outcomes of women with celiac disease: a nationwide historical cohort study. Am J Gastroenterol 1999; 94:2435–2440
21.
Alaedini A, Green PH: Narrative review: celiac disease: understanding a complex autoimmune disorder. Ann Intern Med 2005; 142:289–298
22.
Anjum N, Baker PN, Robinson NJ, Aplin JD: Maternal celiac disease autoantibodies bind directly to syncytiotrophoblast and inhibit placental tissue transglutaminase activity. Reprod Biol Endocrinol 2009; 7:16
23.
Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D: Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3:797–801
24.
Abel KM, Wicks S, Susser ES, Dalman C, Pedersen MG, Mortensen PB, Webb RT: Birth weight, schizophrenia, and adult mental disorder: is risk confined to the smallest babies? Arch Gen Psychiatry 2010; 67:923–930
25.
Dalman C, Allebeck P, Cullberg J, Grunewald C, Koster M: Obstetric complications and the risk of schizophrenia: a longitudinal study of a national birth cohort. Arch Gen Psychiatry 1999; 56:234–240
26.
Cascella NG, Kryszak D, Bhatti B, Gregory P, Kelly DL, McEvoy JP, Fasano A, Eaton WW: Prevalence of celiac disease and gluten sensitivity in the United States Clinical Antipsychotic Trials of Intervention Effectiveness study population. Schizophr Bull 2011; 37:94–100
27.
Dohan FC, Martin L, Grasberger JC, Boehme D, Cottrell JC: Antibodies to wheat gliadin in blood of psychiatric patients: possible role of emotional factors. Biol Psychiatry 1972; 5:127–137
28.
Reichelt KL, Landmark J: Specific IgA antibody increases in schizophrenia. Biol Psychiatry 1995; 37:410–413
29.
Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Alaedini A, Yolken R: Markers of gluten sensitivity and celiac disease in bipolar disorder. Bipolar Disord 2011; 13:52–58
30.
Samaroo D, Dickerson F, Kasarda DD, Green PH, Briani C, Yolken RH, Alaedini A: Novel immune response to gluten in individuals with schizophrenia. Schizophr Res 2010; 118:248–255
31.
Heap GA, van Heel DA: Genetics and pathogenesis of coeliac disease. Semin Immunol 2009; 21:346–354
32.
Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460:748–752
33.
Law MH, Bradford M, McNamara N, Gajda A, Wei J: No association observed between schizophrenia and non-HLA coeliac disease genes: integration with the initial MYO9B association with coeliac disease. Am J Med Genet B Neuropsychiatr Genet 2011; 156B:709–719
34.
Sapone A, Lammers KM, Casolaro V, Cammarota M, Giuliano MT, De Rosa M, Stefanile R, Mazzarella G, Tolone C, Russo MI, Esposito P, Ferraraccio F, Carteni M, Riegler G, de Magistris L, Fasano A: Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. BMC Med 2011; 9:23
35.
Sanders DS, Patel D, Stephenson TJ, Ward AM, McCloskey EV, Hadjivassiliou M, Lobo AJ: A primary care cross-sectional study of undiagnosed adult coeliac disease. Eur J Gastroenterol Hepatol 2003; 15:407–413
36.
Lagerqvist C, Ivarsson A, Juto P, Persson LA, Hernell O: Screening for adult coeliac disease: which serological marker(s) to use? J Intern Med 2001; 250:241–248
37.
Schuppan D, Junker Y, Barisani D: Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009; 137:1912–1933
38.
Verdu EF: Editorial: can gluten contribute to irritable bowel syndrome? Am J Gastroenterol 2011; 106:516–518
39.
Verdu EF, Armstrong D, Murray JA: Between celiac disease and irritable bowel syndrome: the “no man's land” of gluten sensitivity. Am J Gastroenterol 2009; 104:1587–1594
40.
Dohan FC, Grasberger JC: Relapsed schizophrenics: earlier discharge from the hospital after cereal-free, milk-free diet. Am J Psychiatry 1973; 130:685–688
41.
Singh MM, Kay SR: Wheat gluten as a pathogenic factor in schizophrenia. Science 1976; 191:401–402
42.
Harper DN, Nisbet RH, Siegert RJ: Dietary gluten and learning to attend to redundant stimuli in rats. Biol Psychiatry 1997; 42:1060–1066
43.
Dalman C, Broms J, Cullberg J, Allebeck P: Young cases of schizophrenia identified in a national inpatient register: are the diagnoses valid? Soc Psychiatry Psychiatr Epidemiol 2002; 37:527–531
44.
Jorgensen L, Ahlbom A, Allebeck P, Dalman C: The Stockholm Non-Affective Psychoses Study (SNAPS): the importance of including out-patient data in incidence studies. Acta Psychiatr Scand 2010; 121:389–392
45.
Tursi A, Giorgetti G, Brandimarte G, Elisei W: Effect of gluten-free diet on pregnancy outcome in celiac disease patients with recurrent miscarriages. Dig Dis Sci 2008; 53:2925–2928
46.
Baldassarre M, Laneve AM, Grosso R, Laforgia N: Celiac disease: pathogenesis and novel therapeutic strategies. Endocr Metab Immune Disord Drug Targets 2008; 8:152–158
Information & Authors
Information
Published In
History
Received: 8 August 2011
Revision received: 16 December 2011
Accepted: 17 January 2012
Published online: 1 June 2012
Published in print: June 2012
Authors
Funding Information
Dr. Yolken is a member of the Stanley Medical Research Institute Board of Directors and Scientific Advisory Board; the terms of this arrangement are managed by the Johns Hopkins University in accordance with its conflict of interest policies. The other authors report no financial relationships with commercial interests.Supported by the Stanley Medical Research Institute, the Swedish Research Council, and the regional agreement on medical training and clinical research, Stockholm. The funding sources had no role in the design, management, analysis, interpretation, or publication of the study.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).